In 1987, Eli Lilly and Company introduced Humulinﾮ insulin identical to that produced by the human body. Humulin, the world’s first human-health-care product created using recombinant DNA technology, was later applied to the introduction of Humatropeﾮ, a new therapy for growth hormone deficiency in children.